AVIGI Therapeutics, a pioneering biotechnology company leveraging biomimetic rational drug design and advanced chemistry, is pleased to announce the appointment of Dr. Alessandro Noseda as its Medical Advisor. Dr. Noseda brings over three decades of extensive experience in clinical strategy and translational medicine, significantly strengthening AVIGI's mission to develop innovative therapies for unmet medical needs.
Dr. Noseda earned his medical degree from the University of Milan in 1984 and completed postdoctoral studies at the Wake Forest School of Medicine in the United States. Throughout his distinguished career, he has held key leadership roles in leading pharmaceutical and biotechnology companies, contributing significantly to research and development, strategic operations, and global medical technology advancements.
Notably, Dr. Noseda headed the development of previous class of heparanase inhibitors (SST0001) Roneparstat to phase 2 trials.
Dr. Noseda's involvement marks a foundational step for AVIGI Therapeutics as the company advances its paradigm-shifting approach in covalently inhibiting heparanase. His deep understanding of oncology, inflammation, and fibrotic diseases aligns seamlessly with AVIGI's focus on leveraging heparanase biology to address complex medical challenges.
"We are honored to welcome Dr. Alessandro Noseda to AVIGI Therapeutics," said Dr. Vincent Lit, CEO of AVIGI Therapeutics. "His extensive scientific and medical experience in global drug development, coupled with his passion for advancing science-driven innovation, will be instrumental as we advance our development program and bring transformative heparanase-targeted therapies to patients."
Dr. Noseda expressed his enthusiasm about joining the company, stating, "AVIGI Therapeutics has established itself as a pioneer in the field of heparanase-based drug modalities, and I am thrilled to contribute to their efforts. This is an exciting opportunity to work with a talented team and advance innovative solutions for patients in need."
The addition of Dr. Noseda underscores AVIGI Therapeutics' commitment to excellence in scientific innovation and clinical development. As the company moves forward with its robust pipeline, it remains steadfast in its dedication to harnessing cutting-edge science to improve patient outcomes and redefine therapeutic possibilities.
About AVIGI Therapeutics
AVIGI Therapeutics is a biotechnology company dedicated to advancing rationally designed therapeutics. The company focuses on addressing unmet medical needs in oncology, inflammation, and fibrotic diseases.